Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 55, 2746-2751, July 1, 1995]
© 1995 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bögler, O.
Right arrow Articles by Cavenee, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bögler, O.
Right arrow Articles by Cavenee, W. K.

Loss of Wild-Type p53 Bestows a Growth Advantage on Primary Cortical Astrocytes and Facilitates Their in Vitro Transformation1

Oliver Bögler2, H-J. Su Huang and Webster K. Cavenee

Ludwig Institute for Cancer Research [O. B., H-J. S. H., W. K. C.], Department of Medicine [H-J. S. H., W. K. C.], and Center for Molecular Genetics [W. K. C.], University of California San Diego, La Jolla, California 92093-0660

Primary cortical astrocytes were isolated from normal (+/+), heterozygous (+/-), or homozygous (-/-) p53-knockout mice. The normal astrocytes grew slowly and underwent crisis after limited division, while the homozygously defective cells grew rapidly and without contact inhibition. These -/- cells could not initially form colonies in soft agarose but acquired this capability after 10 passages in FCS or basic fibroblast growth factor but not epidermal growth factor. Almost all -/- astrocytes weakly expressed glial fibrillary acidic protein at passage 10 and were also A2B5+ when cultured in basic fibroblast growth factor. Most heterozygous cells resembled normal ones; however, some survived crisis, grew rapidly, and formed colonies. Outgrowing cells had all lost the wild-type p53 allele. These molecular and cellular events mimic the early stages of human brain tumors, suggest a role for p53 in the earliest stages of disease progression, and provide an experimental system to analyze the effects of other tumor-specific mutations in the disease process.

1 Supported by the California Division of the American Cancer Society, Fellowship 1-62-95 (to O. B.).

2 To whom requests for reprints should be addressed, at Ludwig Institute for Cancer Research, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0660.

Received 5/ 3/95. Accepted 5/19/95.




This article has been cited by other articles:


Home page
Cancer Res.Home page
E. J. Peterson, O. Bogler, and S. M. Taylor
p53-Mediated Repression of DNA Methyltransferase 1 Expression by Specific DNA Binding
Cancer Res., October 15, 2003; 63(20): 6579 - 6582.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Shono, P. J. Tofilon, T. S. Schaefer, D. Parikh, T.-J. Liu, and F. F. Lang
Apoptosis Induced by Adenovirus-mediated p53 Gene Transfer in Human Glioma Correlates with Site-specific Phosphorylation
Cancer Res., February 1, 2002; 62(4): 1069 - 1076.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Ueki, R. Nishikawa, Y. Nakazato, T. Hirose, J. Hirato, N. Funada, T. Fujimaki, S. Hojo, O. Kubo, T. Ide, et al.
Correlation of Histology and Molecular Genetic Analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 Astrocytic and Oligodendroglial Tumors
Clin. Cancer Res., January 1, 2002; 8(1): 196 - 201.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. E. Hegi, M. A. Klein, D. Ruedi, P. Chene, M.-F. Hamou, and A. Aguzzi
p53 Transdominance But No Gain of Function in Mouse Brain Tumor Model
Cancer Res., June 1, 2000; 60(11): 3019 - 3024.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
S. Marino, M. Vooijs, H. van der Gulden, J. Jonkers, and A. Berns
Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum
Genes & Dev., April 15, 2000; 14(8): 994 - 1004.
[Abstract] [Full Text]


Home page
Neuro OncolHome page
O. Bogler, F. B. Furnari, A. Kindler-Roehrborn, V. W. Sykes, R. Yung, H.-J. S. Huang, and W. K. Cavenee
SETA: A novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes
Neuro-oncol, January 1, 2000; 2(1): 6 - 15.
[Abstract] [PDF]


Home page
Neuro OncolHome page
M. Nozaki, M. Tada, H. Kobayashi, C.-L. Zhang, Y. Sawamura, H. Abe, N. Ishii, and E. G. Van Meir
Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression
Neuro-oncol, April 1, 1999; 1(2): 124 - 137.
[Abstract] [PDF]


Home page
Cell Growth Differ.Home page
O. Bögler, M. Nagane, J. Gillis, H-J. Su Huang, and W. K. Cavenee
Malignant Transformation of p53-deficient Astrocytes Is Modulated by Environmental Cues in Vitro
Cell Growth Differ., February 1, 1999; 10(2): 73 - 86.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
B. Chen, S. C. Borinstein, J. Gillis, V. W. Sykes, and O. Bogler
The Glioma-associated Protein SETA Interacts with AIP1/Alix and ALG-2 and Modulates Apoptosis in Astrocytes
J. Biol. Chem., June 16, 2000; 275(25): 19275 - 19281.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.